MX2015015162A - Agente de reduccion de acido urico. - Google Patents
Agente de reduccion de acido urico.Info
- Publication number
- MX2015015162A MX2015015162A MX2015015162A MX2015015162A MX2015015162A MX 2015015162 A MX2015015162 A MX 2015015162A MX 2015015162 A MX2015015162 A MX 2015015162A MX 2015015162 A MX2015015162 A MX 2015015162A MX 2015015162 A MX2015015162 A MX 2015015162A
- Authority
- MX
- Mexico
- Prior art keywords
- uric acid
- acid level
- level lowering
- lowering agent
- cyclotyrosylcysteine
- Prior art date
Links
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract 4
- 229940116269 uric acid Drugs 0.000 title abstract 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- NQXUYGGCWWRWBP-LBPRGKRZSA-N (2s)-2-[(1-aminocyclopentanecarbonyl)amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(N)CCCC1 NQXUYGGCWWRWBP-LBPRGKRZSA-N 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 150000007968 uric acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
Abstract
Un agente de reducción de ácido úrico que contiene, como un ingrediente activo, un dipéptido cíclico que contiene tirosina seleccionado a partir del grupo que consiste en ciclotriptofaniltirosina, cicloseriltirosina, cicloproliltirosina, ciclotirosilglicina, ciclotirosiltirosina, ciclofenilalaniltirosina, cicloleuciltirosina, ciclolisiltirosina, ciclohistidiltirosina, cicloalaniltirosina, cicloglutamiltirosina, ciclovaliltirosina, cicloisoleuciltirosina, ciclotreoniltirosina, cicloaspartiltirosina, cicloasparaginiltirosina, cicloglutaminiltirosina, cicloarginiltirosina, ciclometioniltirosina, y ciclotirosilcisteína, o una sal de los mismos; el agente de reducción de ácido úrico de la presente invención tiene una excelente acción de reducir un nivel de ácido úrico, y el agente de reducción de ácido úrico es útil en, por ejemplo, la prevención o el tratamiento de la hiperuricemia, la gota o similares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2014/066424 WO2015194034A1 (ja) | 2014-06-20 | 2014-06-20 | 尿酸値低下剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015015162A true MX2015015162A (es) | 2016-03-15 |
Family
ID=52823346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015162A MX2015015162A (es) | 2014-06-20 | 2014-06-20 | Agente de reduccion de acido urico. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9650415B2 (es) |
| EP (1) | EP3159005A1 (es) |
| JP (1) | JP5690028B1 (es) |
| KR (1) | KR20160022292A (es) |
| CN (1) | CN105407907A (es) |
| AU (1) | AU2014386720B2 (es) |
| BR (1) | BR112015026685A2 (es) |
| CA (1) | CA2904493A1 (es) |
| HK (1) | HK1215797A1 (es) |
| MX (1) | MX2015015162A (es) |
| SG (1) | SG11201507823RA (es) |
| TW (1) | TWI564018B (es) |
| WO (1) | WO2015194034A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6669497B2 (ja) | 2013-06-10 | 2020-03-18 | サントリーホールディングス株式会社 | ジケトピペラジンを含有する植物エキス及びその製造方法 |
| JP6713991B2 (ja) * | 2015-07-02 | 2020-06-24 | サントリーホールディングス株式会社 | アルコール吸収抑制用組成物 |
| WO2017002786A1 (ja) * | 2015-07-02 | 2017-01-05 | サントリーホールディングス株式会社 | Ｇｌｐ－２分泌促進用組成物 |
| JP6669750B2 (ja) * | 2015-07-16 | 2020-03-18 | サントリーホールディングス株式会社 | 環状ジペプチド含有血清カルノシン分解酵素阻害用組成物 |
| JP6666912B2 (ja) * | 2015-07-17 | 2020-03-18 | サントリーホールディングス株式会社 | Ｔｒｐｖ１刺激用組成物 |
| US11219663B2 (en) | 2015-07-27 | 2022-01-11 | Suntory Holdings Limited | Composition containing cyclic dipeptide and sweetening agent |
| JP6719475B2 (ja) * | 2015-09-04 | 2020-07-08 | サントリーホールディングス株式会社 | ウレアーゼ活性阻害剤 |
| CN109562110A (zh) | 2016-05-26 | 2019-04-02 | 株式会社日本阿明诺化学 | 睡眠改善剂 |
| JP2019011303A (ja) * | 2017-07-03 | 2019-01-24 | サントリーホールディングス株式会社 | 環状ジペプチドの製造方法 |
| CN119837994A (zh) * | 2025-01-16 | 2025-04-18 | 广州中医药大学(广州中医药研究院) | 一种环状二肽在改善或治疗血脂异常相关疾病中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5973574A (ja) * | 1982-10-21 | 1984-04-25 | Grelan Pharmaceut Co Ltd | 環状ジペプチド類 |
| AU2001279313B2 (en) * | 2000-08-04 | 2007-03-01 | Ampio Pharmaceuticals, Inc. | Method of using diketopiperazines and composition containing them |
| EP1492794B1 (en) | 2002-03-28 | 2007-12-12 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| ES2572454T3 (es) * | 2003-05-15 | 2016-05-31 | Ampio Pharmaceuticals Inc | Tratamiento de enfermedades mediadas por los linfocitos T |
| JP2006111541A (ja) * | 2004-10-12 | 2006-04-27 | Toyo Shinyaku:Kk | 葛花処理物を含有する経口用肌質改善剤 |
| EP2088143A1 (en) * | 2008-01-24 | 2009-08-12 | Commissariat A L'energie Atomique | Novel inhibitors of mycobacterium tuberculosis complex cytochrome P450 CYP121 |
| SG178213A1 (en) | 2009-12-25 | 2012-03-29 | Suntory Holdings Ltd | Learning motivation improvers |
| JP2013053115A (ja) * | 2011-09-06 | 2013-03-21 | Josho Gakuen | α環状ジペプチドの製造方法 |
| JP6669497B2 (ja) * | 2013-06-10 | 2020-03-18 | サントリーホールディングス株式会社 | ジケトピペラジンを含有する植物エキス及びその製造方法 |
-
2014
- 2014-06-20 HK HK16103771.1A patent/HK1215797A1/zh unknown
- 2014-06-20 KR KR1020157031132A patent/KR20160022292A/ko not_active Ceased
- 2014-06-20 JP JP2014545991A patent/JP5690028B1/ja active Active
- 2014-06-20 SG SG11201507823RA patent/SG11201507823RA/en unknown
- 2014-06-20 BR BR112015026685A patent/BR112015026685A2/pt not_active IP Right Cessation
- 2014-06-20 WO PCT/JP2014/066424 patent/WO2015194034A1/ja not_active Ceased
- 2014-06-20 CN CN201480005474.3A patent/CN105407907A/zh active Pending
- 2014-06-20 EP EP14894840.9A patent/EP3159005A1/en not_active Withdrawn
- 2014-06-20 US US14/787,677 patent/US9650415B2/en not_active Expired - Fee Related
- 2014-06-20 MX MX2015015162A patent/MX2015015162A/es unknown
- 2014-06-20 CA CA2904493A patent/CA2904493A1/en not_active Abandoned
- 2014-06-20 AU AU2014386720A patent/AU2014386720B2/en not_active Ceased
- 2014-09-26 TW TW103133548A patent/TWI564018B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014386720A1 (en) | 2016-01-21 |
| EP3159005A1 (en) | 2017-04-26 |
| US20160159858A1 (en) | 2016-06-09 |
| JP5690028B1 (ja) | 2015-03-25 |
| AU2014386720B2 (en) | 2016-07-21 |
| WO2015194034A1 (ja) | 2015-12-23 |
| KR20160022292A (ko) | 2016-02-29 |
| CN105407907A (zh) | 2016-03-16 |
| BR112015026685A2 (pt) | 2017-07-25 |
| HK1215797A1 (zh) | 2016-09-15 |
| TW201600103A (zh) | 2016-01-01 |
| JPWO2015194034A1 (ja) | 2017-04-20 |
| TWI564018B (zh) | 2017-01-01 |
| CA2904493A1 (en) | 2015-12-20 |
| SG11201507823RA (en) | 2016-01-28 |
| US9650415B2 (en) | 2017-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015015162A (es) | Agente de reduccion de acido urico. | |
| AU2015275507A8 (en) | Cyclic dipeptide-containing composition | |
| NZ733125A (en) | Isoquinoline compounds for the treatment of hiv | |
| NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
| GEP20207159B (en) | Diacylglycerol acyltransferase 2 inhibitors | |
| NZ733135A (en) | Fused pyrimidine compounds for the treatment of hiv | |
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| WO2015003816A3 (en) | Cystobactamides | |
| IL252981B (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| MX2016010451A (es) | Benzoxaboroles microbicidamente activos. | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| NZ730250A (en) | 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators | |
| PH12016501461A1 (en) | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors | |
| EP4268897A3 (en) | Minocycline compounds for biodefense | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| EP3137658A4 (en) | Use of known compounds as d-amino acid oxidase inhibitors | |
| MA39824A (fr) | Composés azole amido-substitués | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| PH12020550222A1 (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| MX2017004819A (es) | Metodos de tratamiento de transtornos urológicos usando sarm. | |
| NZ727715A (en) | Novel heterocyclic compounds having prs enzyme inhibitory effect | |
| EP3251675A4 (en) | Prevention or treatment of uric acid or gout disease |